Eyebot key facts
as of Oct 2026- Developer of an eye examination technology designed to eliminate barriers and provide quality vision care.
- Eyebot is valued at approximately $107.0M as of Oct 2026 (last reported valuation).
- It has raised $28.3M; the latest was Early Stage VC ($20.0M) in Aug 2025.
- Notable investors include US National Science Foundation, General Catalyst, Village Global, AlleyCorp, MassVentures — 10 tracked in total.
- Status: Privately Held (backing).
Eyebot's last reported valuation, Aug 2025. Nothing priced has surfaced since.
- ·Watch Eyebot: the Monday email on marks, rounds and moves
Eyebot funding rounds
No funding rounds for Eyebot are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Eyebot valuation
Eyebot's last reported valuation was $107 million in Aug 2025. No priced round, secondary trade or fund mark has surfaced since.
Eyebot investors
10 investors are on record for Eyebot, including US National Science Foundation, General Catalyst, Village Global and AlleyCorp. By type, the record holds 6 venture capital firms.
About Eyebot
Developer of an eye examination technology designed to eliminate barriers and provide quality vision care. The company offers a freestanding self-serve vision testing terminal that delivers accurate eye prescriptions directly at the point of sale via an automated experience, enabling ophthalmologists to take a proactive approach to eye care for improved quality of life and cost savings.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 24
- Website
- eyebot.co/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.